Highest-materiality recent filing
C4T Phase 1 cemsidomide in RRMM shows 53% ORR at RP2D, MRD negativity, well-tolerated
53% ORR at 100 µg RP2D; 36% ORR across all doses (73 patients, median 7 prior lines).
C4 Therapeutics Q1 2026 net loss $25.1M; cash $268.3M; new Roche DAC collaboration
Revenue $6.2M (down from $7.2M YoY); net loss $25.1M ($0.20 EPS) vs $26.3M ($0.37 EPS).
C4 Therapeutics enters Roche DAC collaboration; $20M upfront, >$1B milestones
$20M upfront from Roche for two DAC programs targeting undisclosed oncology targets.
C4 Therapeutics reports Q4 net loss $20.5M, cash $297M; cemsidomide Phase 2 trial dosed
Q4 revenue $11.0M, net loss $20.5M ($0.18/sh); full-year net loss $105.0M ($1.27/sh).
C4 Therapeutics outlines milestones through 2028; cemsidomide Phase 2 trial on track for Q1 2026
Cemsidomide Phase 2 MOMENTUM trial to begin Q1 2026; recommended Phase 2 dose 100 µg.
C4 Therapeutics reports Q3 net loss $32.2M, raises $125M; cemsidomide 53% ORR at 100 µg
Revenue $11.2M, net loss $32.2M ($0.44 EPS) vs $15.4M revenue and $24.7M loss in Q3 2024.
C4 Therapeutics raises $117M net in underwritten offering of stock and warrants
Offering includes 21.9M shares, pre-funded warrants for 28.7M shares, and Class A/B warrants for 50.6M shares each.
C4 Therapeutics and Pfizer signed a clinical trial collaboration and supply agreement for elranatamab and cemsidomide.
C4 Therapeutics Phase 1 cemsidomide shows 50% ORR at 100 µg in RRMM; Phase 2 planned Q1 2026
50% ORR at 100 µg and 40% ORR at 75 µg cemsidomide + dex in heavily pre-treated RRMM; median DOR 9.3 mo overall.
C4 Therapeutics Q2 net loss $26M; cemsidomide MM ORR 40-50%; FDA align on Phase 2 dose by YE
Net loss of $26.0M ($0.37/share) on revenue $6.5M, down from $12.0M YoY.
C4 Therapeutics Q1 net loss $26.3M; cemsidomide 50% ORR at 100 µg in MM
Revenue $7.2M (up from $3.0M YoY); net loss $0.37/share vs $0.41.
C4 Therapeutics reports FY2024 revenue $35.6M, net loss $1.52/sh; cash runway into 2027
FY2024 revenue $35.6M (vs $20.8M in FY2023); net loss $105.3M ($1.52/sh) vs $132.5M ($2.67).
C4 Therapeutics unveils 2025 milestones; cash runway extended into 2027
Cash, cash equivalents and marketable securities as of Dec 31, 2024 expected to fund operations into 2027.
C4 Therapeutics presents cemsidomide Phase 1 data: 36% ORR in MM, 44% ORR in PTCL at ASH
In MM with dexamethasone, 36% ORR and 45% CBR at 75 µg QD; no dose reductions due to AEs.
C4 Therapeutics appoints Paige Mahaney as CSO effective Oct 28; Stewart Fisher retires
Paige Mahaney, Ph.D., formerly SVP at Exelixis, appointed CSO effective October 28, 2024.
Revenue $3.0M (down from $3.8M YoY); net loss per share $0.41 vs $0.71.
C4 Therapeutics reprices underwater employee options; new exercise prices $19.00 and $11.88
Eligible options with exercise price >$22.00 repriced to $19.00 for senior leadership and $11.88 for other employees.
Upfront payment of $16 million from Merck KGaA; Merck to fund discovery research costs.
C4 Therapeutics reports FY2023 net loss of $132.5M; cash runway extended into 2027
Net loss for FY2023 was $132.5M ($2.67 per share) vs $128.2M ($2.62) in FY2022.
Company posted investor presentation on January 11, 2024, detailing a restructuring plan.
Workforce reduction of ~30% (45 positions) substantially complete by end of Q1 2024; estimated charges of ~$3M.
C4T grants Merck worldwide exclusive license for DACs directed to an initial undisclosed oncology target.
C4 Therapeutics announces positive Phase 1 data for CFT7455 in relapsed/refractory multiple myeloma
Monotherapy dose escalation complete; 22 patients, median 7 prior therapies; 1 PR at 75 µg daily in BCMA-refractory patient.
C4 Therapeutics discontinues CFT8634 BRD9 degrader; Q3 net loss $27.0M
CFT8634 Phase 1 dose escalation failed to show sufficient single-agent efficacy in synovial sarcoma and SMARCB1-null tumors despite high BRD9 degradation; wind-down by Q1 2024.
C4 Therapeutics CFO Lauren White to step down; Kendra Adams named successor
Lauren White resigns as CFO, Treasurer, and principal financial/accounting officer effective September 15, 2023; no disagreement cited.
C4 Therapeutics Q2 net loss $35.9M; cash $286.7M; signs CFT8919 license deal with Betta
Net loss $35.9M ($0.73 per share) vs $27.4M ($0.56) in Q2 2022; revenue fell to $2.7M from $13.8M.
C4 Therapeutics appoints Leonard Reyno, M.D. as Chief Medical Officer effective July 10, 2023
Dr. Reyno receives $550K base salary, $200K sign-on bonus, and up to 40% performance bonus.
C4 Therapeutics licenses CFT8919 to Betta Pharma for Greater China; receives $35M upfront/equity
$10M upfront cash + $25M equity investment from Betta affiliate at $4.49/share (10.2% ownership).
C4 Therapeutics Q1 net loss widens to $34.8M; cash runway into 2025
Net loss of $34.8M ($0.71 per share) vs. $31.6M ($0.65) in Q1 2022; revenue dropped to $3.8M from $7.7M.
C4 Therapeutics FY2022 net loss $128.2M; cash runway to end 2024
Revenue $31.1M in FY2022, down from $45.8M in FY2021 due to Roche agreement termination.
Revenue for 2022 was $31.1M, down from $45.8M in 2021, primarily due to one-time recognition in prior year from Roche agreement termination.
C4 Therapeutics Q3 net loss widens to $32.0M; cash runway to end of 2024
Net loss $32.0M ($0.65/diluted share) vs $24.7M ($0.51) in Q3 2021; revenue $6.8M vs $8.5M.
Kendra R. Adams, the Company's Chief Financial Officer, Head of Corporate Affairs and Treasurer, has been designated as the Company's principal accounting officer, effective May 15, 2026.
Mark Mossler will no longer serve as the Company's Chief Accounting Officer, effective May 15, 2026.
On April 10, 2025, Bruce Downey notified the Board of Directors (the “ Board ”) of C4 Therapeutics, Inc. (the “ Company ”) of his intention to retire from the Board and not to stand for reelection at the 2025 Annual Meeting of Stockholders.
On November 19 , 2024 , the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Steven L. Hoerter as a director of the Company.
On October 15, 2024, the Company announced the appointment of Paige Mahaney, Ph.D. as its Chief Scientific Officer, effective as of October 28, 2024.
On October 11, 2024, Stewart Fisher, Ph.D. informed us of his intent to retire from the role of Chief Scientific Officer of C4 Therapeutics, Inc.
On October 1, 2024, Stewart Fisher, Ph.D. informed us of his intent to retire from the role of Chief Scientific Officer of C4 Therapeutics, Inc.
On October 15, 2024, the Company announced the appointment of Paige Mahaney, Ph.D. as its Chief Scientific Officer, effective as of October 28, 2024.
On August 28, 2024, Malcolm Salter informed the Board of Directors (the “Board”) of C4 Therapeutics, Inc. (the “Company”) of his intention to resign from the Board, effective upon the appointment of his successor.
On August 29, 2024, the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Stephen Fawell, Ph.D. as a director of the Company and a member of the Science and Technology Committee of the Board.
Bruce Downey resigned as Chair of the Board, but will continue to serve as a member of the Board
On November 16, 2023, the Board of Directors (the “ Board ”) of C4 Therapeutics, Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Owen P. Hughes, Jr. as a director of the Company.
Max materiality 0.90 · Median 0.60 · Most common event other_material